PROJECT

Projects

Environmental & Social Review Summary

Project Number

48298

Company Name

3SBio Inc.

Date ESRS Disclosed

Dec 17, 2024

Country

China

Region

East Asia and the Pacific

Last Updated Date

Oct 25, 2025

Environmental Category

B - Limited

Status

Active

Previous Events

Approved : Mar 18, 2024
Signed : May 10, 2024
Invested : Oct 21, 2025

Sector

other

Industry

other

Department

CM4S2 - Regional Industry - MAS Asia & Pac/MAS Services, EAP

Project Description

Founded in 1993, 3SBio Inc. (“3SBio” or “Company”) is a leading pharmaceutical manufacturing and research and development Company focused on the therapeutic areas of recombinant human thrombopoietin (“rhTPO”) and recombinant human erythropoietin (“rhEPO”) nephrology and oncology. Headquartered in Liaoning, China, the Company is listed on the Hong Kong Stock Exchange (1530.HK), selling its products in China and overseas markets.

IFC is considering two A Loans of up to US$200 million in total, to support the Company’s Phase 2 expansion (together the “Project”) comprising: (1) Construction of a Phase 2 research and manufacturing facility within the existing land footprint of its operating facility in Shenyang, Liaoning, China (Location coordinates: 41.70865099626258, 123.2052180834781); (2) a Phase 2 research and manufacturing facility to be constructed within the existing land footprint of its operating Phase 1 facility in Dongguan, Guangdong province, China (Location coordinates: 22.921031829219423, 113.90540680824161); and (3) potential future greenfield construction of a new facility or acquisition of an existing facility at as-yet unidentified overseas locations outside China. Phase 2 of the Shenyang facility is at pre-detailed-design stage, while the Dongguan Phase 2 facility is at pre-production equipment testing stage.

Overview of IFC's Scope of Review

The scope of IFC’s environmental and social (E&S) review of this investment included assessing 3SBio’s systems and capacity to oversee, monitor, and manage operational compliance with IFC’s Performance Standards (PS); the World Bank Group (WBG) Environmental Health & Safety (EHS) EHS General Guidelines and WBG EHS Guidelines for Pharmaceutical and Biotechnology Manufacturing (2007); and national E&S regulatory requirements. IFC’s appraisal is based on: (1) reviewing documents and data from the Company and public domain information such as: environmental impact assessment (EIA) report for the Dongguan Phase 2 facility; 3SBio’s group level 2022 ESG Report; Shenyang facility feasibility study; Company corporate policies and procedures on environmental, health, and safety (e.g. Shanghai facility’s hazardous material management procedures) and Human Resources (HR) management; EHS training records; EHS monitoring and audit reports; facility floor plans, and personnel and material flow diagrams; etc; (2) IFC site visits in October and December 2023 to operating Company facilities at Dongguan (Phase 1), Shanghai, and Shenyang, China. During site visits, interviews were conducted with senior management including the heads of facility, EHS, occupational health and safety (OHS), HR, facility and equipment maintenance departments and their team members, as well as with operational staff at various functional areas and buildings of visited facilities.

E & S Project Categorization and Applicable Standard

Environmental and Social Mitigation Measures

Stakeholder Engagement

Broad Community Support

Environmental & Social Action Plan